Your browser doesn't support javascript.
loading
Ability of epidemiological studies to monitor HPV post-vaccination dynamics: a simulation study.
Bonneault, Mélanie; Delarocque-Astagneau, Elisabeth; Flauder, Maxime; Bogaards, Johannes A; Guillemot, Didier; Opatowski, Lulla; Thiébaut, Anne C M.
Afiliación
  • Bonneault M; Epidemiology and Modelling of Antibiotic Evasion Unit, Institut Pasteur, 75475 Paris, France.
  • Delarocque-Astagneau E; Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, 78180 Montigny-Le-Bretonneux, France.
  • Flauder M; Université Paris-Saclay, UVSQ, Inserm, CESP, High Dimensional Biostatistics Team, 94807 Villejuif, France.
  • Bogaards JA; Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, 78180 Montigny-Le-Bretonneux, France.
  • Guillemot D; Epidemiology and Modelling of Antibiotic Evasion Unit, Institut Pasteur, 75475 Paris, France.
  • Opatowski L; Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, 78180 Montigny-Le-Bretonneux, France.
  • Thiébaut ACM; Department Epidemiology & Data Science, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Epidemiol Infect ; 151: e31, 2023 02 02.
Article en En | MEDLINE | ID: mdl-36727199
ABSTRACT
Genital human papillomavirus (HPV) infections are caused by a broad diversity of genotypes. As available vaccines target a subgroup of these genotypes, monitoring transmission dynamics of nonvaccine genotypes is essential. After reviewing the epidemiological literature on study designs aiming to monitor those dynamics, we evaluated their abilities to detect HPV-prevalence changes following vaccine introduction. We developed an agent-based model to simulate HPV transmission in a heterosexual population under various scenarios of vaccine coverage and genotypic interaction, and reproduced two study designs post-vs.-prevaccine and vaccinated-vs.-unvaccinated comparisons. We calculated the total sample size required to detect statistically significant prevalence differences at the 5% significance level and 80% power. Although a decrease in vaccine-genotype prevalence was detectable as early as 1 year after vaccine introduction, simulations indicated that the indirect impact on nonvaccine-genotype prevalence (a decrease under synergistic interaction or an increase under competitive interaction) would only be measurable after >10 years whatever the vaccine coverage. Sample sizes required for nonvaccine genotypes were >5 times greater than for vaccine genotypes and tended to be smaller in the post-vs.-prevaccine than in the vaccinated-vs.-unvaccinated design. These results highlight that previously published epidemiological studies were not powerful enough to efficiently detect changes in nonvaccine-genotype prevalence.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Epidemiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / EPIDEMIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Epidemiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / EPIDEMIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Francia